Selling a Med Spa: Valuation, Buyer Expectations, and How to Get the Best Price

Med Spa Valuation Multiples in 2026

Med spas trade at 3.0x–6.0x EBITDA in 2026. The spread reflects variation in revenue quality, not just size.

The discount for owner-injector practices is real and measurable. When the medical director or owner performs the majority of revenue-generating procedures, the business cannot survive their departure at full revenue. Buyers price this in — typically 0.5x–1.5x below comparable practices where procedural revenue is distributed across multiple providers.

For full valuation data see the med spa valuation guide and med spa roll-up acquisition data.

Who Is Buying Med Spas in 2026

PE-backed MSO platforms are the most active acquirers at $750K+ EBITDA. National aesthetics consolidators (you know the names) are building geographic density by acquiring established med spas and converting them to their brand, technology stack, and marketing systems. They offer certainty of close (no SBA dependency), fast diligence, and equity rollover for owners who want to participate in platform growth. Their post-close model typically involves operating under a Management Services Agreement while retaining the medical director structure required by state law.

Dermatology and plastic surgery groups are strategic acquirers adding med spa revenue to existing clinical practices. These deals are common in markets where a dermatology practice has existing patient flow they want to monetize through aesthetic services. They pay 4x–6x for established med spas in their geographic market.

Individual operators and PE-backed single-site buyers are SBA-financed buyers acquiring their first or second location. They pay 3x–5x and are most common for med spas under $750K EBITDA. Their diligence focuses heavily on provider contracts and client retention data.

Medical groups and hospital systems are acquiring med spas as patient acquisition tools in markets where elective procedure volume matters. These strategic deals happen at 5x–7x but involve complex corporate approval processes.

What Reduces Your Med Spa's Valuation

The most common value killers in med spa transactions — most of which are preventable:

Injector dependency. If the owner performs 60%+ of Botox and filler revenue, that revenue is at-risk post-transition. The solution: hire and train a clinical team before selling, document their revenue contribution, and get them under employment agreements with non-solicitation clauses.

MSO structure gaps. States with corporate practice of medicine restrictions require med spas to be operated through a Management Services Organization (MSO) structure separating business management from medical direction. If your business does not have a compliant MSO structure, PE buyers cannot acquire it without legal restructuring. Fix this 12–18 months before sale.

Revenue concentration in one procedure. Med spas running 70%+ of revenue from neurotoxin alone have single-procedure concentration risk. Buyers want to see a diversified service mix: neurotoxins, fillers, laser, body contouring, and increasingly weight loss services.

No membership program. Practices with a monthly membership or VIP program have predictable recurring revenue that supports a higher multiple. A 300-member program at $150/month represents $540K in annual contracted revenue — a material valuation premium over transactional-only revenue.

How to Maximize Your Exit Price Before Selling

The 18–24 months before going to market are when multiples are made. Actions that move the number:

Build a multi-provider team. The single highest-leverage action is distributing procedure volume across two or more licensed injectors. Document provider revenue attribution. A practice where the owner generates 30% of procedure revenue rather than 70% commands 1x–2x more in enterprise value.

Launch or expand membership. Monthly membership programs increase revenue predictability. A 200-member program at $150/month generating $360K in annual recurring revenue adds meaningful value at every multiple — and signals business maturity to PE buyers who use recurring revenue as a proxy for retention.

Migrate to a modern EHR and POS. Buyers ask what systems you run. Aesthetic practices running current platforms (Nextech, PatientNow, Symplast, Aesthetic Record) with documented client histories move through diligence faster. Practices on paper charts or outdated systems get asked to represent and warrant data accuracy — which creates seller exposure.

Document client retention data. Average client visit frequency, 12-month retention rate, and LTV by service category. If you do not track these, build the reporting before you go to market. Buyers model these numbers in their acquisition thesis.

Deal Structure for Med Spa Sales

Med spa transactions typically close with one of three structures:

All-cash close. PE-backed MSO buyers often close all-cash with a post-close employment or consulting agreement for the owner. The seller receives full proceeds at closing but agrees to stay for 6–24 months as medical director or clinical consultant to ensure patient and provider continuity.

Cash plus earnout. 10–25% of the purchase price tied to 12–24-month EBITDA or revenue performance. Common when the buyer and seller disagree on post-close revenue trajectory or when a key provider's retention post-sale is uncertain. Negotiate earnout metrics that you control: EBITDA is better than gross revenue.

Equity rollover. Sellers in MSO platform deals frequently roll 15–30% of their equity into the platform. A $3M practice seller who rolls 20% equity into a platform valued at 8x EV/EBITDA could receive $600K–$1.5M at the platform's next recapitalization in 4–5 years. This structure aligns seller incentives with platform performance post-close.

For how to exit your med spa and what to expect from MSO buyers, see the how to sell a med spa guide and the med spa sell page.

Frequently Asked Questions